CCAFU Recommendations 2013: Prostate cancer;Recommandations en onco-urologie 2013 du CCAFU : Cancer de la prostate

Progres en Urologie

Volumn 23, Issue S2, 2013, Pages

  Bastide, C ^a   Beuzeboc, P ^a   Cormier, L ^a   Fromont, G ^a   Hennequin, C ^a   Mongiat Artus, P ^a   Peyromaure, M ^a   Ploussard, G ^a   Renard Penna, R ^a   Rozet, F ^a   Richaud, P ^a   Soulie M ^a   Salomon, L ^a   Azria, D ^b   Coloby, P ^b   Molinie V ^b   Ravery, V ^b   Rebillard, X ^b   Villers, A ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b Membres experts du CCAFU ^*  (France)

Author keywords

Diagnosis; Guidelines; Prostate cancer; Treatment

Indexed keywords

ARTICLE; CANCER DE LA PROSTATE; DIAGNOSIS; DIAGNOSTIC; HUMAN; MALE; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATE TUMOR; RECOMMANDATIONS; TRAITEMENT; TREATMENT;

CANCER DE LA PROSTATE; DIAGNOSIS; DIAGNOSTIC; GUIDELINES; PROSTATE CANCER; RECOMMANDATIONS; TRAITEMENT; TREATMENT;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84893131391     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(13)70048-4     Document Type: Article

References (284)

1. American Joint Committee on Cancer: Cancer staging Handbook. Seventh ed Springer Eds 2010; 525:34.
2. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
3. D'Amico A.V., Moul J., Carrol P.R., Sun L., Lubeck D., Chen M.H. Cancer specific mortality after surgery or irradiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. JCO 2003, 21:2163-2172.
4. Karram S., Trock B.J., Netto G.J., Epstein J.I. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 2011, 35:1351-1355.
5. Delahunt B., Miller R.J., Srigley J.R., Evans A.J., Samaratunga H. Gleason grading: past, present and future. Histopathology 2012, 60:75-86.
6. Samaratunga H., Montironi R., True L., Epstein J.I., Briffiths D.F., Humphrey P.A., et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1: specimen handling. Modern Pathol 2011, 24:6-15.
7. Cheng L., Montironi R., Bostwick D.G., Lopez-Beltran A., Berney D.M. Staging of prostate cancer. Histopathology 2012, 60:87-117.
8. Van der Kwast T., Amin M.B., Billis A., Epstein J.I., Griffiths D., Humphrey P.A., et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathol 2011, 24:16-25.
9. Magi-Galluzzi C., Evans A.J., Delahunt B., Epstein J.I., Griffiths D.F., Van der Kwast T.H., et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 3: Extraprostatic extension, lymphovascular invasion and locally advanced disease. Modern Pathol 2011, 24:26-38.
10. Hoon P., Cheng L., Srigley J.R., Griffiths D., Humphrey P.A., Van der Kwast T.H., et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 5: surgical margins. Modern Pathol 2011, 24:48-57.
11. Berney D.M., Wheeler T.M., Grignon D.J., Epstein J.I., Griffiths D., Humphrey P.A., et al. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathol 2011, 24:39-47.
12. Brock M., Eggert T., Palisaar R.J., Roghmann F., Braun K., Loppenberg B., et al. Multiparametric ultrasound of the prostate: adding contrast enhanced ultrasound to real-time elastography to detect histopathologically confirmed cancer. J Urol 2012, 189:93-98.
13. Hovels A.M., Heesakkers R.A., Adang E.M., Jager G.J., Strum S., Hoogevee Y.L., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:a meta-analysis. Clin Radiol 2008, 63:387-395.
14. Puech P., Rouviere O., Renard-Penna R., Villers A., Devos P., Colombel M., et al. Prostate Cancer Diagnosis: Multiparametric MR-targeted Biopsy with Cognitive and Transrectal US-MR Fusion Guidance versus Systematic Biopsy: Prospective Multicenter Study. Radiology 2013, 268:461-469.
15. Singh A.K., Kruecker J., Xu S., Glossop N., Neeman Z., Choyke P., et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 2008, 101:841-845.
16. Turkbey B., Shah V.P., Pang Y., Bernardo M., Xu S., Kruecker J., et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology 2010, 258:488-495.
17. Barentsz J.O., Richenberg J., Clements R., Choyke P., Verma S., Villeirs G., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757.
18. Sporn M.B., Dunlop N.M., Newton D.L., Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332-1338.
19. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51.
20. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 306:1549-1556.
21. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
22. Gaziano J.M., Sesso H.D., Christen W.G., Bubes V., Smith J.P., Mac-Fadyen J., et al. Multivitamins in the prevention of cancer in men: the Physicians' health Study II randomized controlled trial. JAMA 2012, 308:1871-1880.
23. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
24. Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202.
25. Scardino P.T. The prevention of prostate cancer - the dilemma continues. N Engl J Med 2003, 349:297-299.
26. Walsh P.C. Chemoprevention of prostate cancer. N Engl J Med 2010, 362:1237-1238.
27. Salomon L., Azria D., Bastide C., Beuzeboc P., Cormier L., Cornu F., et al. Comité de Cancérologie de l'AFU. Recommandations en onco-urologie : cancer de la prostate. Prog Urol 2010, 20:S217-S251.
28. Vickers A.J., Savage C., O'Brien M.F., Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403.
29. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., Evans C.L., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
30. Sokoll L.J., Wang Y., Feng Z., Kagan J., Partin A.W., Sanda M.G., et al. [-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Intitute early detection research network validation study. J Urol 2008, 180:539-543.
31. Sokoll L.J., Sanda M.G., Feng Z., Kagan J., Mizrahi I.A., Broyles D.L., et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200.
32. Jansen F.H., Van Schaik R.H.N., Kurstjens J., Horninger W., Klocker H., Bektic J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927.
33. Guazzoni G., Nava L., Lazzeri M., Scattoni V., Lughezzani G., Maccagnano C., et al. p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total psa between 2.0 and 10ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011, 60:214-222.
34. Catalona W.J., Partin A.W., Sanda M.G., Wei J.T., Klee G.G., Bangma C.H., et al. A multicenter study of -2 proPSA combined with PSA and free PSA for Pca detection in 2 to 10ng/ml PSA range. J Urol 2011, 185:1650-1655.
35. Site internet du Memorial Sloan-Kettering Cancer Center. http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx.
36. Crawford E.D., Rove K.O., Trabulsi E.J., Qian J., Drewnowska K.P., Kaminetsky J.C., et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012, 188:1726-1731.
37. Auprich M., Augustin H., Budaüs L., Kluth L., Mannweiler S., Shariat S.F., et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012, 109:1627-1635.
38. Delongchamps N.B., Peyromaure M., Schull A., Beuvon F., Bouazza N., Flam T., et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol 2013, 189:493-499.
39. Haffner J., Lemaitre L., Puech P., Haber G.P., Leroy X., Jones J.S., et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011, 108:E171-E178.
40. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., et al. PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung. Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:125-132.
41. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Prostate-cancer mortality at 11 years follow-up. N Engl J Med 2012, 366:981-990. ERSPC Investigators.
42. Moyer V.A. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012, 157:120-134.
43. Haute Autorité de Santé. Dépistage du cancer de la prostate chez les populations d'hommes présentant des facteurs de risque. Questions/Réponses 4 avril 2012; Available from http://www.has-sante.fr/portail/jcms/c_1238094/depistage-du-cancer-dela-prostate-par-dosage-du-psa-interet-non-demontre-chez-leshommes-presentant-des-facteurs-de-risque.
44. Association française d'urologie. Cancer de la prostate et dépistage. 12/04/12; from http://www.urofrance.org/fileadmin/medias/afu/communiques/2012-03-15_cancer-prostate.pdf.
45. Schröder F.H., Hugosson J., Carlsson S., Tammela T., Maattanen L., Auvinen A., et al. Screening of prostate cancer decreases the risk of developing metastatic disease: findings of the European Randomized Study of Screening of Prostate Cancer. Eur Urol 2012, 62:745-752.
46. Heidenreich A., Abrahamsson P.A., Artibani W., Catto J., Montorsi F., Van Poppel H., et al. Early detection of prostate cancer : European Urology Association of Urology recommendation. Eur Urol 2013, 64:347-354.
47. Han M., Partin A.W., Pound C.R., Epstein J.I., Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
48. Nelson C.P., Rubin M.A., Strawderman M., Montie J.E., Sanda M.G. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002, 59:740-746.
49. Patel D.A., Pesti J.C., McNeal J.E., Gill H., Brooks J.D., King C.R. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005, 23:6157-6162.
50. King C.R., Freedland S.J., Terris M.K., Kane C.J., Amling C.L., Aronson W.J., et al. Optimal timing, cutoff and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007, 69:732-737.
51. Palma D., Tyldsley S., Blood P., Liu M., Morris J., Pickles T. Prostate cohort outcomes initiative: Pretreatment PSA, velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys 2007, 67:1425-1429.
52. D'Amico A.V., Hui-Chen M., Renshaw A.A., Sussman B., Roehl K.A., Catalona W.J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006, 175:S11-S15.
53. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005, 174:2178-2180.
54. Yamamoto S., Yonese J., Kawakami S., Ohkubo Y., Tatokoro M., Komai Y., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007, 52:696-701.
55. Durand X., Xylinas E., Ploussard G., De la Taille A. Urinary biomarkers in prostate cancer: an update. Prog Urol 2010, 20:1184-1191.
56. Egevad L., Mazzuchelli R., Montironi R. Implications of the International Society of urological Pathology modified Gleason grading system. Arch Pathol Lab Med 2012, 136:426-434.
57. Briganti A., Larcher A., Abdollah F., Capitanio U., Gallina A., Suardi N., et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012, 61:480-487.
58. Harnden P., Shelley M.D., Clements H., Coles B., Tyndale-Biscoe R.S., Naylor B., et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 2007, 109:13-24.
59. Yossepowitch O., Bjartell A., Eastham J.A., Graefen M., Guillonneau B.D., Karakiewicz, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009, 55:87-99.
60. Vargas H.A., Akin O., Franiel T., MAzaheri Y., Zheng J., Moskowitz C., et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011, 259:775-784.
61. Bloch B.N., Genega E.M., Costa D.N., Pedrosa I., Smith M.P., Kressel H.Y., et al. Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol 2012, 22:2201-2210.
62. Hovels A.M., Heesakkers R.A., Adang E.M., Jager G.J., Strum S., Hoogeveen Y.L., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008, 63:387-395.
63. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280:975-980.
64. Staerman F., Peyromaure M., Irani J., Gaschignard N., Mottet N., Soulié M., et al. Place de la surveillance active dans le cancer de la prostate à faible risque de progression. Prog Urol 2011, 21:448-454.
65. Wilt T.J., Brawer M.K., Jones K.M., Barry M.J., Aronson W.J., Fox S., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
66. Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J.R., Busch C., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
67. Tosoian J.J., Trock B.J., Landis P., Feng Z., Epstein J.I., Partin A.W., et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011, 29:2185-2190.
68. Klotz L., Zhang L., Lam A., Nam R., Mamedov A., Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
69. Dall'Era M.A., Konety B.R., Cowan J.E., Shinohara K., Stauf F., Cooperberg M.R., et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112:2664-2670.
70. Soloway M.S., Soloway C.T., Eldefrawy A., Acosta K., Kava B., Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010, 58:831-835.
71. Selvadurai E.D., Singhera M., Thomas K., Mohammed K., Woode-Amissah R., Horwich A., et al. Medium-term Outcomes of Active Surveillance for Localised Prostate Cancer. Eur Urol 2013, Feb 18. doi:pii: S0302-2838(13)00132-142.
72. Eggener S.E., Mueller A., Berglund R.K., Ayyathurai R., Soloway C., Soloway M.S., et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2013, 189:S19-S25.
73. Bul M., Zhu X., Valdagni R., Pickles T., Kakehi Y., Rannikko A., et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013, 63:597-603.
74. Mottet N. Place de la surveillance active dans le cancer de prostate: présentation du protocole français. Prog Urol FMC 2008, 18:F12-F16.
75. Moran P.S., O'Neill M., Teljeur C., Flattery M., Murphy L.A., Smyth G., et al. Robot-assisted radical prostatectomy compared with open and laparoscopic approaches: A systematic review and meta-analysis. Int J Urol 2013, 20:312-321.
76. Shikanov S., Woo J., Al-Ahmadi H., Katz M.H., Zagaja G.P., Shalhav A.L., et al. Extrafascial versus interfascial nerve-sparing robotic-assisted laparoscopic radical prostatectomy: comparison of functional outcomes and positive surgical margins characteristics. Urology 2009, 74:611-616.
77. Marien T., Sankin A., Lepor H. Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol 2009, 181:1817-1822.
78. Greco F., Hoda M.R., Wagner S., Reichelt O., Inferrera A., Magno C., et al. Bilateral vs unilateral laparoscopic intrafascial nervesparing radical prostatectomy: evaluation of surgical and functional outcomes in 457 patients. BJU Int 2011, 108:583-587.
79. Salomon L., Azria D., Bastide C., Beuzeboc P., Cormier L., Cornu F., et al. Comité de Cancérologie de l'AFU. Recommandations en onco-urologie : cancer de la prostate. Prog Urol 2010, 20:S217-S251.
80. Selli C., Montironi R., Bono A., Pagano F., Zattoni F., Manganelli J., et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002, 55:508-513.
81. Van der Kwast T.H., Tetu B., Candas B., Gomez J.L., Cusan L., Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology 1999, 53:523-529.
82. Gleave M.E., Goldenberg S.L., Chin J.L., Warner J., Saad F., Klotz H., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500-506.
83. Gravina G.L., Festuccia C., Galatioto G.P., Muzi P., Angelucci A., Ronchi P., et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology 2007, 70:728-733.
84. Soloway M.S., Pareek K., Sharifi R., Wajsman Z., McLeod D., Wood D.P., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002, 167:112-116.
85. Klotz L.H., Goldenberg S.L., Jewett M.A., Fradet Y., Nam R., Barkin J., et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003, 170:791-794.
86. Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002, 90:561-566.
87. Schulman C.C., Debruyne F.M., Forster G., Selvaggi F.P., Zlotta A.R., Witjes W.P. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000, 38:706-713.
88. Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out. Eur Urol 2001, 39:10-14.
89. Prezioso D., Lotti T., Polito M., Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 2004, 72:189-195.
90. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329-2335.
91. Bolla M., Van Poppel H., Collette L., Van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578. European Organization for Research and Treatment of Cancer.
92. Wiegel T., Bottke D., Steiner U., Siegmann A., Golz R., Störkel S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
93. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009, 181:956-962.
94. Créhange G., Chen C.P., Hsu C.C., Kased N., Coakley F.V., Kurhanewicz J., Roach M. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev 2012, 38:956-967.
95. McLeod D.G., See W.A., Klimberg I., Gleason D., Chodak G., Montie J., et al. The bicalutamide 150mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006, 176:75-80.
96. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-529.
97. Wong Y.N., Freedland S., Egleston B., Hudes G., Schwartz J.S., Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009, 27:100-105.
98. Hummel S., Simpson E.L., Hemingway P., Stevenson M.D., Rees A. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-108. iii-iv.
99. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a metaanalysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418.
100. Kuban D.A., Levy L.B., Cheung M.R., Lee A.K., Choi S., Frank S., et al. Long-term failure patterns and survival in a randomized doseescalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
101. Pommier P., Chabaud S., Lagrange J.L., Richaud P., Lesaunier F., Le Prise E., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007, 25:5366-5373.
102. Roach M., DeSilvio M., Valicenti R., Grignon D., Asbell S.O., Lawton C., et al. Whole-pelvis, «mini-pelvis» or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006, 66:647-653.
103. Riou O., Regnault de la Mothe P., Azria D., Ailleres N., Dubois J.B., Fenoglietto P. Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer. J Appl Clin Med Phys 2013, 14:4094.
104. Riou O., Laliberté B., Azria D., Menkarios C., Llacer Moscardo C., Dubois J.B., et al. Implementing intensity modulated radiotherapy to the prostate bed: dosimetric study and early clinical results. Med Dosim 2013, 38:117-121.
105. Jones C.U., Hunt D., McGowan D.G., Amin M.B., Chetner M.P., Bruner D.W., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
106. Quero L., Wong-Hee-Kam S., Rivera S., Hennequin C. Association hormonothérapie et radiothérapie dans le cancer de prostate localement avancé. Bull Cancer 2012, 99:30-36.
107. Bolla M., Van Tienhoven G., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
108. Warde P., Mason M., Ding K., Kirkbride P., Brundage M., Cowan R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
109. Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
110. Mottet N., Peneau M., Mazeron J.J., Molinie V., Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012, 62:213-219.
111. Guzzo T.J., Levin B.M., Lee R., Guo M., Chen Z., Whittington R., et al. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Urology 2008, 71:723-727.
112. Nurani R., Wallner K., Merrick G., Virgin J., Orio P., True L.D. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. J Urol 2007, 178:1968-1973.
113. Davis B.J., Horwitz E.M., Lee W.R., Crook J.M., Stock R.G., Merrick G.S., et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012, 11:6-19.
114. Zelefsky M.J., Kuban D.A., Levy L.B., Potters L., Beyer D.C., Blasko J.C., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
115. Hennequin C., Cormier L., Richaud P., Bastide C., Beuzeboc P., Fromont G., et al. Curiethérapie prostatique : indications et résultats. Prog Urol 2013, 23:378-385.
116. Dosoretz A.M., Chen M.H., Salenius S.A., Ross R.H., Dosoretz D.E., Katin M., et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer 2010, 116:837-842.
117. Taira A.V., Merrick G.S., Galbreath R.W., Wallner K.E., Butler W.M. Natural history of clinically staged low-and intermediaterisk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:349-354.
118. Munro N.P., Al-Qaisieh B., Bownes P., Smith J., Carey B., Bottomley D., et al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10years. Radiother Oncol 2010, 96:34-37.
119. Stone N.N., Potters L., Davis B.J., Ciezki J.P., Zelefsky M.J., Roach M., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:341-346.
120. Rebillard X., Soulié M., Chartier-Kastler E., Davin J.L., Mignard J.P., Moreau J.L., et al. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008, 101:1205-1213.
121. Warmuth M., Johansson T., Mad P. Systematic review of the efficacy and safety of high-intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010, 58:803-815.
122. Crouzet S., Rebillard X., Chevallier D., Rischmann P., Pasticier G., Garcia G., et al. Multicentric oncologic outcomes of high intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 2010, 58:559-566.
123. Crouzet S., Chapelon J.Y., Rouviere O., Mege-Lechevallier F., Colombel M., Tonoli-Catez H., et al. Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients. Eur Urol 2013, Apr 30 [Epub ahead of print].
124. Finley D.S., Pouliot F., Miller D.C., Belldegrun A.S. Primary and salvage cryotherapy for prostate cancer. Urol Clin North Am 2010, 37:67-82.
125. Akaza H., Hinotsu S., Usami M., Arai Y., Kanetake H., Naito S., Hirao Y. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009, 115:3437-3445. Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
126. Crook J.M., O'callaghan C.J., Duncan G., Dearnaley D.P., Higano C.S., Horwitz E.M., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
127. Calais Da Silva F.E., Bono A.V., Whelan P., Brausi M., Marques Queimadelos A., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009, 55:1269-1277.
128. Salonen A.J., Taari K., Ala-Opas M., Viitanen J., Lundstedt S., Tammela T.L. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised Finn Prostate Study VII: quality of life and adverse effects. Eur Urol 2013, 63:111-120. FinnProstate Group.
129. Mottet N., Van Damme J., Loulidi S., Russel C., Leitenberger A., Wolff J.M. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2012, 110:1262-1269. TAP22 Investigators Group.
130. Hussain M., Tangen C.M., Berry D.L., Higano C.S., Crawford E.D., Liu G., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013, 368:1314-1325.
131. Levine G., D'amico A., Berger P., Clark P., Eckel R., Keating N., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 2010, 121:1-8.
132. Oefelein Mg., Ricchiuti V., Conrad W., Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005-1007.
133. http://www.shef.ac.uk/FRAX/.
134. Briot K., Cortet B., Thomas T., Audran M., Blain H., Breuil V., et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012, 79:304-313.
135. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
136. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. N Engl J Med 2013, 368:138-148. COU-AA-302 Investigators.
137. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller M.D., et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012, 367:1187-1197. the AFFIRM Investigators.
138. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study (9182). J Clin Oncol 1999, 17:2506-2513.
139. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moor M.J., et al. Chemotherapy with mitoxantrone plus prednisone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1996, 14:1556-1564.
140. Tannock I.F., De Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. TAX 327 Investigators.
141. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
142. Fizazi K., Le Maitre A., Hudes G., Berry W.R., Kelly W.K., Eymard J.C., et al. Addition of estramus-tine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007, 8:994-1000. Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group.
143. Kellokumpu-Lehtinen P.L., Harmenberg U., Joensuu T., McDermott R., Hervonen P., Ginman C., et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013, 14:117-124.
144. De Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.H., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
145. Beer T.M., Gaezotto M., Henner W.D., Eilers K.M., Wersinger E.M. Multiple cycles of intermittent chemotherapy in metastatic androgenindependent prostate cancer. Br J Cancer 2004, 81:1425-1427.
146. Eymard J.C., Oudard S., Gravis G., Ferrero J.M., Theodore C., Joly F., et al. Docetaxel reintroduction in patients with metastatic hormonerefractory, docetaxel-sensitive, prostate cancer: A retrospective multicenter study (TRIADE). BJU International 2010, 106:974-978.
147. Fizazi K., Carducci M., Smith M., Damio R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
148. Andren O., Garmo H., Mucci L., Andersson S.O., Johansson J.E., Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009, 100:170-173.
149. Lowe B.A., Listrom M.B. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988, 140:1340-1344.
150. Lowe B.A., Listrom M.B. Management of stage A prostate cancer with a high probability of progression. J Urol 1988, 140:1345-1347.
151. Holmberg L., Bill-Axelson A., Helgesen F., Salo J.O., Folmerz P., Haggman M., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002, 347:781-789.
152. Steinberg G.D., Bales G.T., Brendler C.B. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998, 159:1431-1436.
153. Wilt T.J., Brawer M.K., JonesKM, Barry M.J., Aronson W.J., Fox S., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
154. Klotz L., Zhang L., Lam A., Nam R., Mamedov A., Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
155. Carter H.B., Kettermann A., Warlick C., Metter E.J., Landis P., Walsh P.C., et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007, 178:2359-2364.
156. Dall'Era M.A., Konety B.R., Cowan J.E., Shinohara K., Stauf F., Cooperberg M.R., et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112:2664-2670.
157. Patel M.I., DeConcini D.T., Lopez-Corona E., Ohori M., Wheeler T., Scardino P.T. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004, 171:1520-1524.
158. Hardie C., Parker C., Norman A., Eeles R., Horwich A., Huddart R., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005, 95:956-960.
159. Bastian P.J., Carter B.H., Bjartell A., Seitz M., Stanislaus P., Montorsi F., et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009, 55:1321-1330.
160. Ploussard G., Salomon L., Xylinas E., Allory Y., Vordos D., Hoznek A., et al. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance: does the risk of misclassification vary according to biopsy criteria?. J Urol 2010, 183:539-544.
161. Conti S.L., Dall'era M., Fradet V., Cowan J.E., Simko J., Carroll P.R. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009, 181:1628-1633.
162. Bul M., Zhu X., Rannikko A., Staerman F., Valdagni R., Pickles T., et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 2012, 62:195-200.
163. Xia J., Trock B.J., Cooperberg M.R., Gulati R., Zeliadt S.B., Gore J.L., et al. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012, 18:5471-5478.
164. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843-848.
165. Sokoloff M.H., Brendler C.B. Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am 2001, 28:535-543.
166. Stephenson A.J., Kattan M.W., Eastham J.A., Bianco F.J., Yossepowitch O., Vickers A.J., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27. 4300-05.
167. Taira A.V., Merrick G.S., Galbreath R.W., Wallner K.E., Butler W.M. Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:349-354.
168. Peeters S.T., Heemsbergen W.D., Koper P.C., van Putten W.L., Slot A., Dielwart M.F., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24:1990-1996.
169. Blana A., Murat F.J., Walter B., Thuroff S., Wieland W.F., Chaussy C., et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008, 5:1194-1201.
170. Crouzet S, Chapelon JY, Rouviere O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients. Eur Urol 2013 (in press).
171. Heidenreich A., Ohlmann C.H., Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007, 52:29-37.
172. Peneau M., Villers A., Molinie V., Theis D., Soulie M. Indications de la lymphadénectomie ilio-obturatrice dans le cancer de prostate cliniquement localisé. Prog Urol 2004, 14:287-294.
173. Bill Axelson A., Holmberg L., Rutuu M., Haqqman M., Andersson S.O, Bratell S. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
174. Bill-Axelson A., Holmberg L., Filen F., Ruutu M., Garmo H., Busch C., et al. Radical prostatectomy versus wachfulle waiting in localized prostate cancer: the Scandinavian prostate cancer group 4 randomized trial. J Natl Cancer Inst 2008, 100:144-154.
175. Sokoloff M.H., Brendler C.B. Indications and contraindications for nerve-sparing radical prostatectomy. Urol Clin North Am 2001, 28:535-543.
176. Bastide C., Soulié M., Davin Jl, Rossi D. Marges positives après prostatectomie totale : aspects techniques et valeur pronostique. Prog Urol 2007, 17:182-188.
177. D'Amico Av., Whittington R., Malkowicz Sb., Schultz D., Tomaszewski Je., Wein A. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer 2000, 88:2110-2115.
178. D'amico Av, Whittington R., Malkowicz S.B., Cote K., Loffredo M., Schultz D., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281-286.
179. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco F.J., Dotan Z.A., Fearn P.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancerrecurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98:715-717.
180. Peeters S.T., Heemsbergen W.D., Koper P.C., Van Putten W.L., Slot A., Dielwart M.F., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24:1990-1996.
181. Pollack A., Zagars G., Starkschall G., Antolak J., Lee J., Huang E., et al. Prostate cancer radiation dose response: results of the M.D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
182. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S., et al. Randomized trial comparing iridium implant plus externalbeam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
183. Zietman A.L., Bae K., Slater J.D., Shipley W.U., Efstathiou J.A., Coen J.J. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol 2010, 28:1106-1112.
184. Beckendorf V., Guerif S., Le Prisé E., Cosset J.M., Bougnoux A., Chauvet B., et al. 70Gy versus 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063.
185. Kuban D.A., Tucker S.L., Dong L., Starkschall G., Huang E.H., Cheung M.R., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
186. Al-Mamgani A., Heemsbergen W.D., Levendag P.C., Lebesque J.V. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol 2010, 96:13-18.
187. Zelefsky M.J., Pei X., Chou J.F., Schechter M., Kollmeier M., Cox B., et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011, 60:1133-1139.
188. D'Amico A., Manola J., Loffredo M., Renshaw A., Dellacroce A., Kantoff P. 6-month suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004, 292:821-827.
189. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299:289-295.
190. Jones C.U., Hunt D., McGowan D.G., Amin M.B., Chetner M.P., Bruner D.W., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
191. Bolla M. Intermediate-and high-risk prostate cancer: a plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapy. Eur Urol 2011, 60:1140-1141.
192. Graversen P.H., Nielsen K.T., Gasser T.C., Corle D.K., Madsen P.O. RADICAL prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990, 36:493-498.
193. Steineck G., Helgesen F., Adolfsson J.W., Johansson J.E., Norlen B.J., et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790-796. Scandinavian Prostatic Cancer Group Study Number 4.
194. Bul M., Van Den Bergh R.C., Zhu X., Rannikko A., Vasarainen H., Bangma C.H., et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 2012, 110:1672-1677.
195. Godtman R.A., Holmberg E., Khatami A., Stranne J., Hugosson J. Outcome following active surveillance of men with screendetected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol 2013, 63:101-107.
196. Dahabreh I.J., Chung M., Balk E.M., Yu W.W., Mathew P., Lau J., et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med 2012, 156:582-590.
197. Abern M.R., Aronson W.J., Terris M.K., Kane C.J., Presti J.C., Amling C.L., et al. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate 2013, 73:409-417.
198. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
199. Ho A.Y., Burri R.J., Cesaretti J.A., Stone N.N., Stock R.G. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:16-22.
200. Dattoli M., Wallner K., True L., Cash J., Sorace R. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007, 110:551-555.
201. Stock R.G., Yamalachi S., Hall S.J., Stone N.N. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010, 183:546-550.
202. Taira A.V., Merrick G.S., Galbreath R.W., Wallner K.E., Butler W.M. Natural history of clinically staged low-and intermediaterisk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:349-354.
203. Zebentout O., Apardian R., Beaulieu L., Harel F., Martin Ag, Vigneault E. Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience. Cancer Radiother 2010, 14:183-188.
204. Hinnen K.A., Battermann J.J., Van Roermund J.G., Moerland M.A., Jürgenliemk-Schulz I.M., Frank S.J., et al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010, 76:1433-1438.
205. Munro Np., Al-Qaisieh B., Bownes P., Smith J., Carey B., Bottomley D., et al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. Radiother Oncol 2010, 96:34-37.
206. Salembier C., Lavagnini P., Nickers P., Mangili P., Rijnders A., Polo A., et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007, 83:3-10.
207. Nag S., Beyer D., Friedland, Grimm P., Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
208. Ragde H., Korb L., Elgamal A., Grado G., Nadir B. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000, 89:135-141.
209. Hurwitz M.D., Halabi S., Archer L., Mcginnis L.S., Kuettel M.R., Dibiase S.J., et al. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer 2011, 117:5579-5588.
210. Stock R.G., Yalamanchi S., Hall S.J., Stone N.N. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010, 183:546-550.
211. Ho A.Y., Burri R.J., Cesaretti J.A., Stone N.N., Stock R.G. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:16-22.
212. Sylvester J.E., Grimm P.D., Blasko J.C., Millar J., Orio P.F., Skoglund S., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy;Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
213. Rebillard X., Soulié M., Davin J.L. Traitement par HIFU du cancer de la prostate : revue de la littérature et indications de traitement. Prog Urol 2003, 13:1428-1457. et CCAFU.
214. Blana A., Murat F.J., Walter B., Thuroff S., Wieland W.F., Chaussy C., et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008, 53:1194-1201.
215. Crouzet S., Rebillard X., Chevallier D., Rischmann P., Pasticier G., Garcia G., et al. Multicentric oncologic outcomes of highintensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 2010, 58:559-566.
216. Shelley M., Wilt T.J., Coles B., Mason M.D. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007, 18. CD005010.
217. Donnelly B.J., Saliken J.C., Brasher P.M., Ernst S.D., Rewcastle J.C., Lau H., et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010, 116:323-330.
218. Pisters L.L. Cryotherapy for prostate cancer: ready for prime time?. Curr Opin Urol 2010, 20:218-222.
219. Bahn D., De Castro Abreu A.L., Gill I.S., Hung A.J., Silverman P., Gross M.E., et al. Focal cryotherapy for clinically unilateral, lowintermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012, 62:55-63.
220. Evangelista L., Guttilla A., Zattoni F., Muzzio P.C. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013, 63:1040-1048.
221. Bolla M., Van Tienhoven G., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
222. Pilepich M., Winter K., Lawton C., Krisch R., Wolkov H., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
223. Warde P., Mason M., Ding K., Kirkbride P., Brundage M., Cowan R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
224. Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
225. Mottet N., Peneau M., Mazeron J.J., Molinie V., Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012, 62:213-219.
226. Bolla M., de Reijke T.M., Van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
227. Horwitz E.M., Bae K., Hanks G.E., Porter A., Grignon D.J., Brereton H.D., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
228. Rozet F., Hennequin C., Fromont G., Mongiat-Artus P., Bastide C., Beuzeboc P., et al. Tumeurs de la prostate à haut risque. Revue du CC-AFU. Prog Urol 2011, 21:901-908.
229. Studer U.E., Collette L., Whelan P., Albrecht W., Casselman J., de Reijke T., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008, 53:941-949.
230. Lattouf J.B., Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?. Eur Urol 2003, 43:333-336.
231. Soulié M., Beuzeboc P., Cornud F., Eschwege P., Gaschignard N., Grosclaude P., et al. Comité de Cancérologie de l'Association Française d'Urologie. Recommandations 2007 en onco-urologie. Cancer de la prostate. Prog Urol 2007, 17:1157-1230.
232. Simmons M.N., Stephenson Aj., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007, 51:1175-1184.
233. Roach M., Hanks G., Thames H., Schellhammer P., Shipley W.U., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
234. Grimm P.D., Blasko J.C., Sylvester J.E., Meier R.M., Cavanagh W. 10 year biochemical (PSA) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phy 2001, 51:31-40.
235. Caloglu M., Ciezki J. Prostate specific antigen bounce after prostate brachytherapy: review of a confusing phenomen. Urology 2009, 74:1183-1190.
236. Thompson A., Keys M., Pickles A., Palma D., Moravan V., Spadinger I., et al. Évaluation of the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kikentics distinguish PSA failure for PSA bounces?. Int J Rad Oncol Biophy 2010, 78:415-421.
237. Schiavina R, Ceci F, Brunocilla E, Vagnoni V, Gacci M, Castellucci P, et al. The Dilemna of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques. Curr Radiopharm 2013, in press.
238. Blana A., Brown S.C., Chaussy C., Conti G.N., Eastham J.A., Ganzer R., et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009, 104:1058-1062.
239. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommandations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
240. Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007, 51:1175-1184.
241. Roach M., Hanks G., Thames H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
242. Blana A., Brown S.C., Chaussy C., Conti G.N., Eastham J.A., Ganzer R., et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009, 104:1058-1062.
243. Lu-Yao G., Stukel T.A., Yao S.L. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004, 17:2285-2290.
244. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommandations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
245. Partin A.W., Pearson J.D., Landis P.K., Carter H.B., Pound C.R., Clemens J., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994, 43:649-659.
246. Boonsirikamchai P., Kaur H., Kuban D.A., Jackson E., Hou P., Choi H. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. AJR Am J Roentgenol 2012, 198:228-236.
247. Cirillo S., Petracchini M., Scotti L., Gallo T., Macera A., Bona M.C., et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009, 19:761-769.
248. Sella T., Schwartz L.H., Swindle P.W., Onyebucchi C.N., Scardino P.T., Scher H.J., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004, 231:379-385.
249. Akin O., Gultekin D.H., Vargas H.A., Zheng J., Moskowitz C., Pei X., et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 2011, 21:1970-1978.
250. Kim C.K., Park B.K., Lee H.M. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009, 29:391-397.
251. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
252. Vilain D., Hameg A., Tainturier C. Scintigraphie osseuse chez les patients présentant des métastases en uro-oncologie : revue de la littérature. Prog Urol 2008, 18:S202-S207.
253. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol 2012, 199:278-291.
254. Price D.T., Coleman R.E., Liao R.P., Robertson C.N., Polascik T.J., DeGrado T.R. Comparison of [18 F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002, 168:273-280.
255. Lecouvet F.E., El Mouedden J., Collette L., Coche E., Danse E., Jamar F., et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. Eur Urol 2012, 62:68-75.
256. Eschmann S.M., Pfannenberg A.C., Rieger A., Aschoff P., Muller M., Paulsen F., et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007, 46:161-168.
257. Buskirk S.J., Pisansky T.M., Schild S.E., MacDonald O.K., Wehle M.J., Kozelsky T.F., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006, 176:985-990.
258. Cotter S.A., Chen M.H., Moul J.W., Lee W.R., Koontz B.F., Anscher M.S., et al. Salvage radiation in men after prostate-specific antigen failure and the rsik of death. Cancer 2011, 117:3925-3932.
259. Stephenson A.J., Scardino P.T., Kattan M.W., Pisansky T.M., Slawin K.M., Klein E.A., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Onc 2007, 25:2035-2041.
260. Kuban D.A., Levy L.B., Cheung M.R., Lee A.K., Choi S., Frank S., et al. Long-term failure patterns and survival in a randomized doseescalation trial for prostate cancer Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
261. Paparel P., Soulie M., Mongiat-Artus P., Cornud F., Borgogno C. Prostatectomie de rattrapage après radiothérapie externe pour cancer de la prostate : indications, morbidité et résultats. Une revue du CC-AFU. Prog Urol 2012, 20:317-326.
262. Chade D.C., Eastham J., Graefen M., Hu J.C., Karnes R.J., Klotz L., et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012, 61:961-971.
263. Heidenreich A., Richter S., Thuer D., Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010, 57:437-443.
264. Chen C.P., Weinberg V., Shinohara K., Roach M., Nash M., Gottschalk A., et al. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int J Radiat Oncol Biol Phys 2013, 86:324-329.
265. Burri R.J., Stone N.N., Unger P., Stock R.G. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:1338-1344.
266. Ramey S.J., Marshall D.T. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 2012, Sep 28 [Epub ahead of print].
267. Crouzet S., Murat F.J., Pommier P., Poissonnier L., Pasticier G., Rouviere O., et al. Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. Radiother Oncol 2012, 105:198-202.
268. Mouraviev V., Spiess P.E., Jones J.S. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 2012, 61:1204-1211.
269. Pinover W., Horwitz E., Hanlon A., Uzzo R.G., Hanks G.E. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003, 97:1127-1133.
270. Souhami L., Bae K., Pilepich M., Sandler H. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys 2010, 78:1301-1306.
271. Crook J.M., O'Callaghan C.J., Duncan G., Dearnaley D.P., Higano C.S., Horwitz E.M., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
272. Crouzet S, Chapelon JY, Rouviere O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients. Eur Urol 2013, in press.
273. Pasticier G., Chapet O., Badet L., Ardiet J.M., Poissonnier L., Murat F.J., et al. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 2008, 72:1305-1309.
274. Riviere J., Bernhard J.C., Robert G., Wallerand H., Deti E., Maurice-Tison S., et al. Salvage radiotherapy after high-intensity focussed ultrasound for recurrent localised prostate cancer. Eur Urol 2010, 58:567-573.
275. Tannock I.F., De Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. TAX 327 Investigators.
276. De Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.H., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
277. Beer T.M., Gaezotto M., Henner W.D., Eilers K.M., Wersinger E.M. Multiple cycles of intermittent chemotherapy in metastatic androgenindependent prostate cancer. Br J Cancer 2004, 81:1425-1427.
278. Eymard J.C., Oudard S., Gravis G., Ferrero J.M., Theodore C., Joly F., et al. Docetaxel reintroduction in patients with metastatic hormone-refractory, docetaxel-sensitive, prostate cancer: A retrospective multicenter study (TRIADE). BJU International 2010, 106:974-978.
279. Fizazi K., Carducci M., Smith M., Damio R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
280. Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
281. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., De Souza P., et al. N Engl J Med 2013, 368:138-148. COU-AA-302 Investigators.
282. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. IMPACT Study Investigators.
283. De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
284. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller M.D., et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012, 367:1187-1197. the AFFIRM Investigators.